Primo Chemicals Ltd
PRIMOPrimo Chemicals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (2 weeks in) while the P/E sits at the 55th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +14.7% year on year, and 179% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Primo Chemicals Ltd trades at ₹23.7, in a downtrend and 2 weeks into that stage. That is +1.6% against its own 200-day average. It sits at 50% of a 52-week range of ₹21 to ₹26. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a downtrend — week 2 of stage 4, confirmed. At ₹23.7 it trades +1.6% versus its 200-day average and sits at 50% of its 52-week range (₹21–₹26).
Against the market, two honest reads. Cumulative: over the last 5 months the stock moved −2% while the NIFTY 500 moved −1% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-14) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Primo Chemicals Ltd trades at 36.8× P/E, mid-range by its own standards (55th percentile). Its long-run median P/E is 33.5×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.8× is mid-range by its own standards (55th percentile), against a long-run median of 33.5× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Primo Chemicals Ltd was paying for profit growth of about 25.1% a year. Profit itself has compounded 13.4% a year over the past 5 years. Today the market pays 36.8× P/E, the 55th percentile of its own 4-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Primo Chemicals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.4% | −7.1% | +20.3% | — |
| Profit | +275.0% | −52.2% | +13.4% | — |
| EPS | +320.0% | −51.9% | +3.5% | — |
4-Factor Sector Score
46.3/100 — rank 4 of 7 in Chemicals - Inorganic - Caustic Soda/Soda Ash · 72% evidence confidence
Primo Chemicals Ltd scores 46.3 out of 100 against the 7 companies it is compared with in Chemicals - Inorganic - Caustic Soda/Soda Ash, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 13.7 + 11.7 + 9.5 + 11.4 = 46.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Primo Chemicals Ltd reported ₹140 Cr of revenue in the Jun 26 quarter, −1.2% year on year. Over 5 years it has compounded at 20.3% a year. The last full year, FY26, came in at ₹562 Cr. The last four reported quarters add to ₹560 Cr.
FY26 revenue came in at ₹562 Cr (+2.4% on the year), capping 5 years at 20.3% compound. The latest quarter (Jun 26) printed ₹140 Cr, −1.2% year on year.
Pace check: the last four quarters averaged −2.6% growth against the decade's 20.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −2.7% over the last 4 quarters against +17.0%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Primo Chemicals Ltd's operating margin is 14.8% in the Jun 26 quarter, +0.5 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −6.0% to 27.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 14.8%, +0.5 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −6.0%–27.0%.
Why the margin moved: operating margin went +0.5 pp year on year while gross margin went −0.4 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Primo Chemicals Ltd earned ₹4.7 Cr of net profit in the Jun 26 quarter, +14.7% year on year. Full-year FY26 profit was ₹15.0 Cr. The 5-year compound rate is 13.4%. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹4.1 Cr. 4 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹4.7 Cr, +14.7% year on year. On the full year, FY26 printed ₹15.0 Cr (+275.0%), and the 5-year compound rate is 13.4%.
Why profit moved: revenue contributed −1.2% and the margin +0.5 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −35.7% vs revenue −2.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 179% of Primo Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹65.0 Cr of operating cash against ₹15.0 Cr of profit. After ₹27.0 Cr of capital spending, ₹38.0 Cr was left as free cash.
FY26: operating cash of ₹65.0 Cr against reported profit of ₹15.0 Cr, leaving free cash of ₹38.0 Cr after ₹27.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 179% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 179%: the cash cycle stretched 172 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Primo Chemicals Ltd's cash conversion cycle runs 20 days in FY26, up from −152 days in FY21. Capital spending ran ₹134 Cr over the last 3 years. At FY26 sales of ₹562 Cr each day of that cycle holds about ₹1.5 Cr, so roughly ₹31.0 Cr sits inside the business at any moment.
FY26: debtors at 21 days, inventory at 34 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 20 days, looser than FY21's −152.
The full loop: cash goes out to suppliers and production on day 0; stock waits 34 days to sell; customers pay about 21 days after that; and suppliers themselves are paid at 34 days — netting out to the 20-day cycle.
In money terms: at FY26 sales of ₹562 Cr, each day of the cycle holds about ₹1.5 Cr — so the 20-day loop keeps roughly ₹31.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹134 Cr over the last 3 fiscal years against ₹144 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹12.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Primo Chemicals Ltd earns a ROCE of 6% in FY26. That is up from a trough of −2% in FY24. Return on invested capital clears the cost of that capital by −7.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 2.7% net margin on 0.81× asset turns.
FY26 ROCE is 6%, recovered from a FY24 trough of −2% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 2.7% net margin × 0.81× asset turns × 1.70× balance-sheet leverage ≈ 3.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 4.7% − 12.0% = a −7.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Primo Chemicals Ltd carries ₹131 Cr of borrowings against ₹406 Cr of equity in FY26, a debt-to-equity of 0.32. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1.0 Cr to ₹131 Cr. Capital spending ran ₹134 Cr across the last 3 of those years.
FY26: borrowings of ₹131 Cr against equity of ₹406 Cr — a debt-to-equity of 0.32. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1.0 Cr to ₹131 Cr while capital spending ran ₹134 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 1.0 points of Primo Chemicals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 32.4% of the company. Foreign institutions moved +0.1 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +1.0 points over 8 quarters to 32.4%; Foreign institutions: +0.1 points over 8 quarters to 0.3%; Domestic institutions: +0.0 points over 8 quarters to 1.9%.
Why the register moved: promoters drove it (+1.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Primo Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1TGV Sraac LtdTGVSL | 65.6/100Favorable setup76% evidence | 24.8/35 Revenue 7.6% · PAT 16.9% · OPM change -1 pp 95% evidence | 15.8/25 ROCE 13% · OPM 18% 76% evidence | 12.2/20 P/E 8.2× · PEG — 50% evidence | 12.8/20 RS sector 2.4% · RS bench 1.7% · 1Y -20.3%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 24.8 + 15.8 + 12.2 + 12.8 = 65.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Gujarat Alkalies & Chemicals LtdGUJALKALI | 62.5/100Mixed-positive evidence84% evidence | TURNING | 21.6/35 Revenue 7.1% · PAT 100% · OPM change 9 pp 74% evidence | 7.4/25 ROCE 1.4% · OPM 18% 100% evidence | 13.5/20 P/E 78× · PEG 0.15 65% evidence | 20.0/20 RS sector 25.5% · RS bench 21% · 1Y 19.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 7.4 + 13.5 + 20 = 62.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Tuticorin Alkali Chemicals & Fertilizers LtdTUTIALKA | 49.9/100Mixed-negative evidence76% evidence | 12.1/35 Revenue 9.3% · PAT -6.7% · OPM change -11.2 pp 95% evidence | 18.9/25 ROCE 22.2% · OPM 13.3% 76% evidence | 7.9/20 P/E 21.6× · PEG — 50% evidence | 11.0/20 RS sector -5.3% · RS bench 6.1% · 1Y -18.7%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 12.1 + 18.9 + 7.9 + 11 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Primo Chemicals Ltdthis pagePRIMO | 46.3/100Mixed-negative evidence72% evidence | ASLEEP | 13.7/35 Revenue -2.7% · PAT -15.5% · OPM change 0.5 pp 95% evidence | 11.7/25 ROCE 6.5% · OPM 14.8% 95% evidence | 9.5/20 P/E 36.8× · PEG — 50% evidence | 11.4/20 RS sector — · RS bench 5.3% · 1Y —1 of 9 weeks ahead 25% evidence |
| Exact sum: 13.7 + 11.7 + 9.5 + 11.4 = 46.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5GHCL LtdGHCL | 44.5/100Mixed-negative evidence96% evidence | BASING | 7.7/35 Revenue -3.7% · PAT -24.2% · OPM change -6 pp 88% evidence | 18.1/25 ROCE 17.4% · OPM 22% 100% evidence | 11.7/20 P/E 8.5× · PEG 1.31 100% evidence | 7.0/20 RS sector -12.2% · RS bench -15.8% · 1Y -24.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.7 + 18.1 + 11.7 + 7 = 44.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemfab Alkalis LtdCHEMFAB | 35.8/100Mixed-negative evidence71% evidence | BASING | 18.0/35 Revenue -16.2% · PAT 95.3% · OPM change 1.5 pp 95% evidence | 3.7/25 ROCE 1% · OPM 13.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -30.3% · RS bench -11% · 1Y -41.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18 + 3.7 + 10 + 4.1 = 35.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tata Chemicals LtdTATACHEM | 26.9/100Adverse evidence80% evidence | ASLEEP | 9.1/35 Revenue 2% · PAT -80% · OPM change -4 pp 100% evidence | 6.6/25 ROCE 3.4% · OPM 13% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.2/20 RS sector -13.4% · RS bench -17% · 1Y -34.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 9.1 + 6.6 + 10 + 1.2 = 26.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Primo Chemicals Ltd's share price today?
Primo Chemicals Ltd trades at ₹23.7. The company is valued at ₹575 Cr. The stock sits at 50% of its 52-week range of ₹21–₹26, +1.6% versus its 200-day average. On the tape, the price is in a downtrend, 2 weeks in. — as of 11 September 2026.
What were Primo Chemicals Ltd's latest quarterly results?
Primo Chemicals Ltd reported revenue of ₹140 Cr and net profit of ₹4.7 Cr for the Jun 26 quarter. Revenue fell 1.2% and profit rose 14.7% year on year. Earnings per share were ₹0.19. The operating margin was 14.8%, 0.5 pp higher than a year earlier. — as of 11 September 2026.
What is Primo Chemicals Ltd's revenue?
Primo Chemicals Ltd reported revenue of ₹140 Cr in the Jun 26 quarter, −1.2% year on year. For the full FY26 fiscal year, revenue was ₹562 Cr (+2.4%). Over the last 5 years revenue compounded at 20.3% a year. — as of 11 September 2026.
What is Primo Chemicals Ltd's profit?
Primo Chemicals Ltd earned ₹4.7 Cr of net profit in the Jun 26 quarter, +14.7% year on year. Full-year FY26 profit was ₹15.0 Cr. The operating margin ran 14.8% in the latest quarter. — as of 11 September 2026.
What is Primo Chemicals Ltd's market cap?
Primo Chemicals Ltd's market capitalisation is ₹575 Cr at a share price of ₹23.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Primo Chemicals Ltd's P/E ratio?
Primo Chemicals Ltd trades at a P/E of 36.8×, at the 55th percentile of its own 4-year range, against a long-run median of 33.5×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Primo Chemicals Ltd pay a dividend?
No — Primo Chemicals Ltd has recorded a dividend payout of 0% of profit in each of its last 6 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Primo Chemicals Ltd overvalued?
On its own history, Primo Chemicals Ltd looks mid-range: its P/E of 36.8× sits at the 55th percentile of its 4-year range (long-run median 33.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Primo Chemicals Ltd growing?
Yes — Primo Chemicals Ltd is growing: latest-quarter revenue −1.2% year on year, profit +14.7%, and the margin +0.5 pp at 14.8%. The 5-year compound rates are 20.3% (revenue) and 13.4% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Primo Chemicals Ltd performing?
Primo Chemicals Ltd is in a downtrend, 2 weeks in. Its latest quarter's revenue fell 1.2% and profit rose 14.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Primo Chemicals Ltd in an uptrend?
No — the price is in a downtrend (week 2 of stage 4), trading +1.6% versus its 200-day average and at 50% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Primo Chemicals Ltd beating the market?
Not lately — on a trailing-13-week view Primo Chemicals Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-08-14), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5 months the stock moved −2% against the NIFTY 500's −1% — behind the index over the full window. — as of 11 September 2026.
Will Primo Chemicals Ltd's share price go up?
This page publishes no price forecast for Primo Chemicals Ltd. What it measures instead: the share price is ₹23.7, the price is in a downtrend 2 weeks in. Its P/E of 36.8× sits at the 55th percentile of its own 4-year range. — as of 11 September 2026.
Who owns Primo Chemicals Ltd?
Promoters hold 32.4% of Primo Chemicals Ltd, foreign institutions 0.3%, domestic institutions 1.9% and the public 65.4% (latest quarter). The biggest move on the register over the last two years: Promoters added 1.0 points over 8 quarters. — as of 11 September 2026.
Does Primo Chemicals Ltd have too much debt?
It is moderate — Primo Chemicals Ltd's debt-to-equity is 0.32, and operating profit covers the interest bill 4×. FY26 borrowings were ₹131 Cr against equity of ₹406 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Primo Chemicals Ltd's capex?
Primo Chemicals Ltd spent ₹134 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹27.0 Cr, with ₹12.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Primo Chemicals Ltd's cash flow?
Primo Chemicals Ltd generated ₹65.0 Cr of operating cash flow in FY26 and ₹38.0 Cr of free cash flow after ₹27.0 Cr of capital spending. Reported profit that year was ₹15.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Primo Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 179% of Primo Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹65.0 Cr against reported profit of ₹15.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Primo Chemicals Ltd in its business cycle?
Primo Chemicals Ltd's FY26 operating margin was 12.0%, against a 6-year band of −6.0%–27.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 14.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Primo Chemicals Ltd's price assume?
At its price on 13 June 2026, Primo Chemicals Ltd was priced for profit growth of about 25.1% a year. Profit itself has compounded 13.4% a year over the past 5 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Primo Chemicals Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Primo Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Primo Chemicals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!